Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $129.43

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been assigned an average rating of “Buy” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $130.69.

A number of research analysts have commented on AXSM shares. Mizuho decreased their target price on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 31st. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC restated a “buy” rating and set a $133.00 price target on shares of Axsome Therapeutics in a research note on Monday, January 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th.

Axsome Therapeutics Price Performance

AXSM opened at $91.93 on Wednesday. The business has a fifty day moving average of $92.27 and a 200 day moving average of $89.53. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The stock has a market cap of $4.45 billion, a P/E ratio of -14.08 and a beta of 1.04. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same period last year, the firm posted ($1.32) EPS. As a group, sell-side analysts anticipate that Axsome Therapeutics will post -4.61 EPS for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in Axsome Therapeutics during the second quarter valued at about $27,000. WCM Investment Management LLC boosted its position in Axsome Therapeutics by 0.3% during the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock worth $10,191,000 after acquiring an additional 347 shares during the period. US Bancorp DE lifted its holdings in shares of Axsome Therapeutics by 0.3% during the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company’s stock valued at $11,964,000 after buying an additional 421 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Axsome Therapeutics during the second quarter worth $47,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.